Follow-up of patients with chronic nodular prurigo

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022555

Enrollment

100

Registered

2020-10-07

Start date

2020-11-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L28.1 L28.2

Interventions

Group 1: Patients with chronic nodular prurigo, who have participated in the PRISM trial in Germany and who were treated with nalbuphine In this study, the course of chronic prurigo with regard to pr

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Diagnosis: chronic nodular prurigo (L28.1/L28.2) - Participation in the PRISM trial completed (study arm 1) - Study-naive patients (study arm 2) - NRS >3 (study arm 2) - 18 years of age or older

Exclusion criteria

Exclusion criteria: - No understanding of the German language

Design outcomes

Primary

Measure	Time frame
- Stage and activity of the prurigo skin lesions (IGA-CPG stage score, IGA-CPG activity score), as well as dynamics of the skin lesions (no change, improved, deteriorated) - Pruritus intensity (worst pruritus intensity of the last 24 hours on the NRS, average pruritus intensity of the last 24 hours on the NRS, worst pruritus intensity of the last 4 weeks on the NRS), and dynamics of the pruritus intensity (dynamic pruritus score).	—

Measure

Time frame

- Stage and activity of the prurigo skin lesions (IGA-CPG stage score, IGA-CPG activity score), as well as dynamics of the skin lesions (no change, improved, deteriorated) - Pruritus intensity (worst pruritus intensity of the last 24 hours on the NRS, average pruritus intensity of the last 24 hours on the NRS, worst pruritus intensity of the last 4 weeks on the NRS), and dynamics of the pruritus intensity (dynamic pruritus score).

—

Secondary

Measure	Time frame
- Demographic data (age, sex, height, weight) - General data (family status, employment, education) - Medical history (cause underlying prurigo, atopy, comorbidities, medication) - Current and prior therapy of prurigo	—

Countries

Germany

Contacts

Public ContactManuel Pereira

Klinik für Hautkrankheiten und Kompetenzzentrum chronischer Pruritus (KCP), Universitätsklinikum Münster

manuelpedro.pereira@ukmuenster.de00492518357470

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026